Safety of growth hormone replacement therapy in adults

Bibliographys

• NOLTE W, RADISCH C, ARMSTRONG VW HOFNER M, VON ZUR MOHLEN A: The effect of recombinant human GH replacement therapy on lipoprotein(a) and other lipid parameters in adults with acquired GH deficiency: results of a double-blind and placebo-controlled trial. Eur. Endocrinol (1997) 137:459–466.
   PubMed Web of Science ®Google Scholar
• WEBSTERJM, STEWART M, AL-MASKARI M et al.: The effect of growth hormone replacement therapy for up to 12 months on lipoprotein composition and lipoprotein(a) in growth hormone-deficient adults. Atherosclerosis(1997) 133:115–121.
   PubMed Web of Science ®Google Scholar
• VAHL N, JORGENSEN JO, HANSEN TB et al.: The favourable effects of growth hormone (GH) substitution on hypercholesterolaemia in GH-deficient adults are not associated with concomitant reductions in adiposity. A 12 month placebo-controlled study. Int. J. Obes. Relat. Metab. Disord. (1998) 22:529–536.
   Google Scholar
• LEESE GP, WALLYMAHMED M, WIERINGA G, VANHEYNINGEN C, MACFARLANE IA: Apo E phenotype and changes in serum lipids in adult patients during growth hormone replacement. Eur. Endocrinol (1999) 140:174–179.
   PubMed Web of Science ®Google Scholar
• PFEIFER M, VERHOVEC M, ZIZEK B, PREZELJJ, POREDOS P, CLAYTON RN: Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. I Clin. Endocrinol Metab. (1999) 84:453–457.
   PubMed Web of Science ®Google Scholar
• LEVINE GN, KEANEY JF, VITA JA: Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N. Engl. J. Med. (1995) 332:512–521.
   PubMed Web of Science ®Google Scholar
• BOSTOM AG, CUPPLES LA, JENNERJL et al.: Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. J. Am. Med. Assoc. (1996) 276:544–548.
   PubMed Web of Science ®Google Scholar
• JOHANSSON JO, LANDIN K, TENGBORN L, ROSEN T, BENGTSSON BA: High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults. Arterioscler. Thromb. Vasc Biol. (1994) 14:434–437.
   PubMed Web of Science ®Google Scholar
• JOHANSSON JO, LANDIN K, JOHANNSSON G, TENGBORN L, BENGTSSON BA: Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults. Thromb. Haemost. (1996) 76:422–428.
   PubMed Web of Science ®Google Scholar
• CHRIST ER, CUMMINGS MH, LUMB PJ, CROOK MA, SONKSEN PH, RUSSELL-JONES DL: Growth hormone (GH) replacement therapy reduces serum sialic acid concentrations in adults with GH-deficiency: a double-blind placebo-controlled study. Clin. Endocrinol (Oxf) (1999) 51:173–179.
   PubMed Web of Science ®Google Scholar
• SESMILO G, BILLER BM, LLEVADOT Jet al.: Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann. Intern. Med. (2000) 133:111–122.
   Google Scholar
• •First clinical indication that GH can reduce systematic inflammatory cardiovascular risk factors.
   Google Scholar
• SESMILO G, BILLER BM, LLEVADOT J et al.: Effects of growth hormone (GH) administration on homocyst(e)ine levels in men with GH deficiency: a randomized controlled trial. j Clin. Endocrinol Metab. (2001) 86:1518–1524.
   PubMed Web of Science ®Google Scholar
• BESSON A, SALEMI S, GALLATI S et al.: Reduced longevity in untreated patients with isolated growth hormone deficiency. Clin. Endocrinol Metab. (2003) 88:3664–3667.
   Google Scholar
• BRADA M, RAJAN B, TRAISH D et al:The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas. Clin. Endocrinol (Ox]:) (1993) 38:571–578.
   PubMed Web of Science ®Google Scholar
• TURNER HE, STRATTON IM, BYRNE JV, ADAMS CB, WASS JA: Audit of selected patients with nonfunctioning pituitary adenomas treated without irradiation - a follow-up study. Clin. Endocrinol (Ox]:) (1999) 51:281–284.
   PubMed Web of Science ®Google Scholar
• ATTANASIO AF, LAMBERTS SW, MATRANGA AM et al.: Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Clin. Endocrinol Metab. (1997) 82:82–88.
   Google Scholar
• MARD G, LUNDIN K, BORG G, JONSSON B, LINDBERG A: Growth hormone replacement therapy in adult hypopituitary patients with growth hormone deficiency: combined data from 12 European placebo-controlled clinical trials. Endocrinol Metab. (1994) l(Suppl. A):43–49.
   Google Scholar
• CUNEO RC, JUDD S, WALLACE JD et al.: The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-Deficient Adults. I Clin. Endocrinol Metab. (1998) 83:107–116.
   PubMed Web of Science ®Google Scholar
• BENGTSSON BA, EDEN S, ERNEST I, ODEN A, SJOGREN B: Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med. Scand. (1988) 223:327–335.
   Google Scholar
• DELHOUGNE B, DENEUX C, ABS R et al.: The prevalence of colonic polyps in acromegaly: a colonoscopic and pathological study in 103 patients. I Gin. Endocrinol Metab. (1995) 80:3223–3226.
   PubMed Web of Science ®Google Scholar
• JENKINS PJ, FAIRCLOUGH PD, RICHARDS T et al.: Acromegaly, colonic polyps and carcinoma. Clin. Endocrinol (Ox!:) (1997) 47:17–22.
   PubMed Web of Science ®Google Scholar
• RENEHAN AG, O'DWYER ST, SHALET SM: Colorectal neoplasia in acromegaly: the reported increased prevalence is overestimated. Gut (2000) 46:440–441.
   PubMed Web of Science ®Google Scholar
• HANKINSON SE, WILLETT WC, COLDITZ GA et al: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet (1998) 351:1393–1396.
   PubMed Web of Science ®Google Scholar
• BENGTSSON BA, KOPPESCHAAR HP, ABS R et al.: Growth hormone replacement therapy is not associated with any increase in mortality. KIMS Study Group. Clin. Endocrinol Metab. (1999) 84:4291–4292.
   PubMed Web of Science ®Google Scholar
• SVENSSON J, BENGTSSON BA, ODEN A, ROSEN T, JOHANNSSON G: The incidence of malignant disease and cardiovascular morbidity in hypopituitary patients with or without growth hormone replacement therapy. The Endocrine Society Annual Meeting, Philadelphia, USA (2003)344.
   Google Scholar